Navigation Links
Evidence in the field of CVD in pregnancy is sparse, but the condition remains a concern:
Date:8/30/2011

Pre-existing heart disease in pregnancy remains a concern. Complications are frequent and in some cases may be life-threatening for both the mother and her child. In Europe maternal heart disease has now become the major cause of maternal death during pregnancy.

As interim data from the ESC's special registry on pregnancy in cardiac disease suggests, the numbers of women at risk is not in decline, mainly because of today's older age at first pregnancy and with it a concomitant increase in risks of diabetes, hypertension and obesity.

Professor Jolien Roos-Hesselink, joint chairman of the ESC registry together with Professor Roger Hall (Norwich, UK), reported that the most frequently diagnosed condition in the registry population was congenital heart disease, found in around 60% of subjects. More than 1300 women have been enrolled into the registry so far - from 28 countries and 60 centres; they consist of 869 women with congenital heart disease, 333 with valvular heart disease patients, 79 with cardiomyopathy and 24 with ischaemic heart disease.

Professor Roos-Hesselink said that evidence in this field is sparse, with randomised trials impossible to perform: "So the only way to improve our knowledge of the factors which determine outcome in pregnant women with heart disease is to gather data on a large number of pregnancies and try to find patterns of outcome which correlate with management strategies. In this way we might determine the areas of danger for both mother and child and the best forms of treatment."

It was because of the need to generate relevant data in areas such as this, that the concept of European registries was developed in 2006. Data collection in the pregnancy and CVD registry began in 2008, with information recorded on CVD diagnosis, medication, cardiac complications, obstetric complications, and pregnancy outcome at six months.

An interim analysis of these pregnancies was presented at the ESC Congress but, said Professor Roos-Hesselink, data collection continues and it is clear larger numbers will be required to obtain meaningful conclusions.

However, results so far reflect a very high hospitalisation rate during pregnancy: 338 patients (26% of all pregnancies) were hospitalised, 203 of cardiac cause. Maternal death occurred in 13 patients (1%) and fetal death in 59 cases (4.5%). These death rates, said Professor Roos-Hesselink, are significantly higher than normal; maternal mortality is in the order of 100 times higher and fetal mortality 10 times higher. There was also a high rate of delivery by Caesarean section of around 40%.

She added that no single cause for the high mortality rate is as yet clear, but the further analysis and larger numbers of the study should provide stringer evidence. "We are analysing patterns of therapy as well trying to identify the particular underlying cardiac conditions associated with mortality," she said.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-633-473-335
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
2. Evidence-based care and outcomes improve at Get With The Guidelines-Stroke hospitals
3. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
4. More Evidence That Swings in Blood Pressure Raise Stroke Risk
5. Cellular pathway could provide evidence of how cancer and obesity are linked
6. Palladians Distinguished Clinicians Present at APTAs National CSM Convention in San Diego on Evidenced Informed Management of Chronic Low Back Pain Without Surgery
7. Pew Applauds Federal Grant Program Supporting State Expansion of Evidence-Based Home Visitation
8. Elseviers Journal of Evidence-Based Dental Practice celebrates 10th year with special issue
9. Evidence-based medicine theory can be applied to frequent flying says US professor
10. No Evidence That Lithium Helps in ALS
11. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: